Trial Profile
A Randomized Double Blind Active Comparator Controlled Phase III Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Amoxicillin/omeprazole/rifabutin (Primary) ; Amoxicillin; Omeprazole
- Indications Helicobacter pylori infections
- Focus Registrational; Therapeutic Use
- Acronyms ERADICATE Hp 2
- Sponsors RedHill Biopharma
- 12 Mar 2024 According to a RedHill Biopharma media release,the company announced the issue of a new U.S. patent covering Talicia as an all-in-one fixed-dose combination of amoxicillin, omeprazole and rifabutin and its use for the treatment of helicobacter pylori (H. pylori) infection (Patent No. 11,931,463 to be issued March 19, 20244)
- 01 Aug 2023 According to a RedHill Biopharma media release, Gaelan Medical received marketing approval from the United Arab Emirates (UAE) Ministry of Health for Talicia (omeprazole magnesium, amoxicillin and rifabutin).
- 04 Nov 2022 Results of post hoc analysis of pooled, modified intention-to-treat data from 293 subjects in the Phase 3 trials (NCT01980095/ NCT03198507) presented at The Obesity Society: ObesityWeek 2022.